bg-img9.jpg

Transitioning to a New Biobank Model at a Time of Change: An AstraZeneca & Fisher BioServices Perspective

Posted by Karen Roberts on Nov 21, 2017 10:00:00 AM

AZNewBiobankModel_poster blog pic-1.jpgThe AstraZeneca (AZ) UK Biobank offers long-term storage of, and rapid access to, ~1 million human biological samples (HBS) from AZ Oncology clinical trials, collaborators and commercial sources. A variety of sample types are managed including normal tissue, tumor tissue, blood/plasma/serum, urine and other excreta, FFPE blocks, glass slides and genetic samples (DNA/blood).

The recent rise in personalized medicine has increased demand for rapid access to high quality samples. Sample requests are for both on-study and exploratory research, include internal AZ and external collaborator/CRO analysis, and help drive biomarker strategies, generate disease linkage data, inform patient selection decisions, and determine mechanisms of resistance to targeted therapies.

In 2014, AZ made the decision to create a mixed outsourcing model for its AZ UK Biobank, with off-site storage at Fisher BioServices (FBS) holding the majority of the clinical trial samples and AZ Alderley Park (AP) staff managing customer interactions and the strategic direction of the service.

This InfoPoster describes how AZ was able to meet the increased demand for rapid access to high quality samples by partnering with Fisher BioServices. To learn more about the challenges and benefits of implementing a mixed outsourcing biobank model, download the poster below!

AZ InfoPoster_NewBiobankModel_cover.jpg

Download InfoPoster